Quantitation of the Monoclonal Antibody Rituximab Using VAMS, Impact-Assisted Extraction, Trypsin Digestion and LC-MRM
Stability of ASO in Tissue Matrix
Resolving Issues with Matrix Effect Oligonucleotides
Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
Vaccine Development Blog/Podcast
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Vaccine Development Realities (COVID-19 and Beyond)
Up Close and Personal with Francis Douville
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Francis Douville joined the Altasciences team in 2018, as Senior Vice President, Technical Operations, for our preclinical services.
Re: IND-enabling bioanalytical support provided by Altasciences
We were very pleased with the way the team at Altasciences negotiated the challenges encountered during the bioanalytical development of our complex compound as part of our IND-enabling package. The scientific excellence applied, and the adaptability demonstrated, allowed for successful development of our bioanalytical methods.